Canada Markets closed

PharmaTher Holdings Ltd. (PHRM.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
0.2650-0.0150 (-5.36%)
At close: 03:43PM EST
Full screen
Previous Close0.2800
Bid0.2550 x N/A
Ask0.2800 x N/A
Day's Range0.2400 - 0.2700
52 Week Range0.1900 - 1.2400
Avg. Volume195,976
Market Cap18.248M
Beta (5Y Monthly)N/A
PE Ratio (TTM)6.62
EPS (TTM)0.0400
Earnings DateOct. 27, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
  • Baystreet

    Stocks in play: PharmaTher Inc

    Is pleased to provide an update on the Company’s psilocybin pharmaceutical development programs. The ...

  • GlobeNewswire

    Revive Therapeutics Provides Update of Psilocybin Pharmaceutical Programs

    IRB approval to initiate Phase 2 study for methamphetamine abuse disorders Advancing psilocybin oral thin film, microneedle patch and biosynthesis programs TORONTO, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on the Company’s psilocybin pharmaceutical de

  • GlobeNewswire

    PharmaTher Announces FDA Approval of Investigational New Drug (IND) Application for Ketamine to Treat ALS

    TORONTO, Jan. 12, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a company focused on the development and commercialization of specialty ketamine prescription-based products, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted an investigator-initiated investigational new drug ("IND") application to proceed with a Phase 2 clinical trial (the “Study”) evaluating ketamine in the treatment of Amyotrophic Late